kinase inhibitors as first-line therapy in five hospitals between October 2008 and August 2018. The risk group classification differences between the MSKCC and the IMDC models were evaluated using criteria of agreement (identical risk group in both the MSKCC and IMDC models) and disagreement (not identical risk group in both the MSKCC and IMDC models). The agreement of risk stratification between the MSKCC and IMDC models was evaluated using Cohen's coefficient. Oncological outcomes were compared between the agreement and disagreement groups.
INTRODUCTION AND OBJECTIVES:
Sarcopenia is a state of degenerative skeletal muscle wasting induced by cancer cachexia. To evaluate the prognostic impact of change in skeletal muscle mass (SMM) during first-line sunitinib therapy on oncological outcomes in metastatic renal cell carcinoma (mRCC).
METHODS: Sixty-nine patients were evaluated retrospectively. The skeletal muscle index (SMI) was calculated based on computed tomography images obtained before the initiation (pretreatment SMI) and after two cycles of sunitinib treatment (posttreatment SMI). The change in SMM was evaluated based on the value of DSMI which was calculated as [(posttreatment SMI-pretreatment SMI)/ pretreatment SMI] Â 100. We divided the patients as follows: DSMI < 0 (SMM decrease) and DSMI ! 0 (SMM maintenance). Oncological outcomes were compared between the groups.
RESULTS: A decrease in SMM was observed in 38 patients (55.1%). Progression-free survival (PFS) and overall survival (OS) after sunitinib therapy initiation were significantly shorter in patients with DSMI < 0 than in those with DSMI ! 0 (median PFS: 9.53 vs. 28.4 months, p < 0.0001; OS: 19.8 vs. 52.6 months, p [ 0.0001). The DSMI was an independent factor for PFS (HR: 3.25, p [ 0.0002) and OS (HR: 4.53, 95% CI: 2.15-10.5, p < 0.0001). The objective response rate was significantly lower in patients with DSMI < 0 than in those with DSMI ! 0 (23.7% vs. 51.6%, p [ 0.0164).
CONCLUSIONS: Decreased SMM during first-line sunitinib therapy can be a useful marker of outcome prediction for mRCC.
